| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 26 | 2020 | 1209 | 3.080 |
Why?
|
| Brain Ischemia | 15 | 2020 | 418 | 2.480 |
Why?
|
| Leukoaraiosis | 6 | 2019 | 45 | 1.200 |
Why?
|
| Thrombolytic Therapy | 8 | 2020 | 195 | 1.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2012 | 214 | 0.810 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.730 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2020 | 126 | 0.700 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 178 | 0.610 |
Why?
|
| Amyloid beta-Peptides | 3 | 2015 | 321 | 0.600 |
Why?
|
| Quality of Health Care | 2 | 2014 | 528 | 0.590 |
Why?
|
| Sleep | 2 | 2015 | 240 | 0.570 |
Why?
|
| Amnesia | 2 | 2015 | 9 | 0.540 |
Why?
|
| Atrial Fibrillation | 4 | 2020 | 879 | 0.540 |
Why?
|
| Anticoagulants | 4 | 2019 | 525 | 0.530 |
Why?
|
| Cerebral Infarction | 3 | 2015 | 85 | 0.440 |
Why?
|
| Health Status Disparities | 1 | 2016 | 147 | 0.440 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2006 | 27 | 0.420 |
Why?
|
| Humans | 57 | 2024 | 65121 | 0.410 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2007 | 235 | 0.400 |
Why?
|
| Heparin | 2 | 2006 | 118 | 0.390 |
Why?
|
| Blood Pressure | 1 | 2015 | 526 | 0.390 |
Why?
|
| Aspergillosis | 4 | 1994 | 35 | 0.380 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2012 | 67 | 0.360 |
Why?
|
| Aged | 26 | 2020 | 14955 | 0.340 |
Why?
|
| Neuroimaging | 2 | 2014 | 164 | 0.340 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 350 | 0.340 |
Why?
|
| Sex Characteristics | 1 | 2012 | 214 | 0.330 |
Why?
|
| Severity of Illness Index | 8 | 2019 | 1559 | 0.320 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 96 | 0.320 |
Why?
|
| Male | 36 | 2020 | 31039 | 0.320 |
Why?
|
| Hypoglossal Nerve Diseases | 1 | 2009 | 2 | 0.310 |
Why?
|
| Dysarthria | 1 | 2009 | 7 | 0.310 |
Why?
|
| Internal Capsule | 1 | 2009 | 11 | 0.310 |
Why?
|
| Acute Disease | 6 | 2009 | 663 | 0.310 |
Why?
|
| Tongue | 1 | 2009 | 18 | 0.310 |
Why?
|
| Movement Disorders | 1 | 2009 | 26 | 0.300 |
Why?
|
| Middle Aged | 23 | 2020 | 18264 | 0.300 |
Why?
|
| Hospitalization | 1 | 2016 | 1392 | 0.290 |
Why?
|
| Aspirin | 2 | 2007 | 172 | 0.290 |
Why?
|
| Telemedicine | 2 | 2014 | 363 | 0.280 |
Why?
|
| Female | 30 | 2020 | 34013 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 1113 | 0.280 |
Why?
|
| Hypertension | 3 | 2016 | 612 | 0.280 |
Why?
|
| Heart Failure | 1 | 2016 | 954 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2024 | 2244 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 1656 | 0.260 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 5609 | 0.260 |
Why?
|
| White Matter | 2 | 2019 | 126 | 0.250 |
Why?
|
| Alzheimer Disease | 5 | 2009 | 765 | 0.250 |
Why?
|
| Coronary Angiography | 1 | 2007 | 212 | 0.250 |
Why?
|
| Brain | 4 | 2017 | 1604 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 2 | 2012 | 183 | 0.240 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 42 | 0.240 |
Why?
|
| Polysomnography | 1 | 2006 | 60 | 0.240 |
Why?
|
| Cerebral Hemorrhage | 5 | 2017 | 100 | 0.230 |
Why?
|
| Risk Factors | 8 | 2020 | 5429 | 0.230 |
Why?
|
| Cognition Disorders | 2 | 2005 | 223 | 0.230 |
Why?
|
| Cardiac Catheterization | 1 | 2007 | 293 | 0.230 |
Why?
|
| Sleep Wake Disorders | 1 | 2006 | 77 | 0.220 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2024 | 2 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2020 | 5785 | 0.210 |
Why?
|
| Peptide Fragments | 2 | 2007 | 417 | 0.210 |
Why?
|
| Retrospective Studies | 12 | 2024 | 6862 | 0.210 |
Why?
|
| HIV-1 | 5 | 2001 | 706 | 0.200 |
Why?
|
| Presenilin-1 | 4 | 2009 | 66 | 0.200 |
Why?
|
| Ticlopidine | 1 | 2003 | 47 | 0.200 |
Why?
|
| Injections, Intravenous | 4 | 2009 | 159 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 179 | 0.190 |
Why?
|
| Disintegrins | 1 | 2022 | 4 | 0.180 |
Why?
|
| Thrombospondins | 1 | 2022 | 6 | 0.180 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 7 | 0.180 |
Why?
|
| Cholesterol | 3 | 2009 | 261 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 1993 | 125 | 0.180 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 43 | 0.170 |
Why?
|
| Th2 Cells | 1 | 2001 | 93 | 0.170 |
Why?
|
| Receptors, CCR5 | 1 | 2001 | 59 | 0.170 |
Why?
|
| Models, Biological | 1 | 2006 | 1192 | 0.170 |
Why?
|
| Th1 Cells | 1 | 2001 | 171 | 0.170 |
Why?
|
| Algorithms | 1 | 2006 | 1048 | 0.160 |
Why?
|
| Time Factors | 6 | 2019 | 3762 | 0.160 |
Why?
|
| Incidence | 2 | 2019 | 1418 | 0.160 |
Why?
|
| Hematoma | 2 | 2019 | 84 | 0.160 |
Why?
|
| Bed Rest | 1 | 2019 | 11 | 0.160 |
Why?
|
| Vitamin K | 1 | 2019 | 15 | 0.150 |
Why?
|
| Secondary Prevention | 3 | 2006 | 165 | 0.150 |
Why?
|
| Mechanical Thrombolysis | 1 | 2019 | 36 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 69 | 0.140 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 25 | 0.140 |
Why?
|
| Heterozygote | 3 | 2009 | 173 | 0.140 |
Why?
|
| Dementia | 2 | 2003 | 280 | 0.130 |
Why?
|
| Neuropsychological Tests | 2 | 1996 | 410 | 0.130 |
Why?
|
| Prevalence | 3 | 2020 | 1445 | 0.130 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 710 | 0.120 |
Why?
|
| Occipital Lobe | 1 | 1996 | 17 | 0.120 |
Why?
|
| Eligibility Determination | 1 | 2016 | 37 | 0.120 |
Why?
|
| India | 2 | 2014 | 164 | 0.120 |
Why?
|
| California | 1 | 2016 | 177 | 0.120 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 1996 | 62 | 0.120 |
Why?
|
| Glioblastoma | 2 | 1998 | 161 | 0.110 |
Why?
|
| Endovascular Procedures | 3 | 2017 | 626 | 0.110 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 117 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 134 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2007 | 576 | 0.110 |
Why?
|
| Clodronic Acid | 1 | 1994 | 4 | 0.110 |
Why?
|
| Amphotericin B | 1 | 1994 | 21 | 0.100 |
Why?
|
| Phagocytes | 1 | 1994 | 51 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 318 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2020 | 2102 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 930 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 483 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 827 | 0.100 |
Why?
|
| Lethal Dose 50 | 4 | 1994 | 16 | 0.100 |
Why?
|
| Phosphatidic Acids | 1 | 1993 | 8 | 0.100 |
Why?
|
| Aspergillus fumigatus | 1 | 1993 | 38 | 0.100 |
Why?
|
| Prognosis | 3 | 2009 | 1785 | 0.100 |
Why?
|
| Recurrence | 2 | 2005 | 657 | 0.100 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2014 | 87 | 0.100 |
Why?
|
| Mannose | 1 | 1993 | 22 | 0.100 |
Why?
|
| Liposomes | 4 | 1994 | 116 | 0.090 |
Why?
|
| Cognition | 1 | 1996 | 508 | 0.090 |
Why?
|
| Tetanus | 1 | 1991 | 5 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 164 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 991 | 0.090 |
Why?
|
| Macrophage Activation | 1 | 1992 | 115 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 1991 | 30 | 0.090 |
Why?
|
| Mutation | 4 | 2009 | 2658 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 1994 | 869 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 555 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2019 | 2619 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 2483 | 0.080 |
Why?
|
| Phagocytosis | 1 | 1992 | 257 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 804 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 433 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2009 | 9 | 0.080 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2009 | 27 | 0.080 |
Why?
|
| Edema | 1 | 1989 | 42 | 0.080 |
Why?
|
| Macrophages | 2 | 1993 | 1037 | 0.080 |
Why?
|
| Peripheral Nerves | 1 | 1989 | 33 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1163 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 481 | 0.080 |
Why?
|
| Eye | 1 | 1989 | 59 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2014 | 497 | 0.080 |
Why?
|
| Hand | 1 | 2009 | 76 | 0.070 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 21 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2016 | 754 | 0.070 |
Why?
|
| Plant Oils | 1 | 1989 | 63 | 0.070 |
Why?
|
| Adult | 9 | 2019 | 17356 | 0.070 |
Why?
|
| Polyenes | 3 | 1993 | 5 | 0.070 |
Why?
|
| Muscles | 1 | 1989 | 179 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1149 | 0.070 |
Why?
|
| Hyperparathyroidism | 1 | 1988 | 8 | 0.070 |
Why?
|
| Virus Replication | 3 | 2001 | 323 | 0.070 |
Why?
|
| Thalamic Diseases | 1 | 1988 | 2 | 0.070 |
Why?
|
| Antiviral Agents | 3 | 1996 | 321 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1698 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 727 | 0.070 |
Why?
|
| Tissue Distribution | 3 | 1993 | 293 | 0.070 |
Why?
|
| Muscular Diseases | 1 | 1988 | 50 | 0.070 |
Why?
|
| Electroencephalography | 2 | 2024 | 156 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Platelet Function Tests | 1 | 2007 | 11 | 0.070 |
Why?
|
| Thromboxane A2 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Platelet Activation | 1 | 2007 | 31 | 0.070 |
Why?
|
| Animals | 8 | 2005 | 21324 | 0.070 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2007 | 87 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 1219 | 0.060 |
Why?
|
| Pedigree | 1 | 2007 | 193 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 196 | 0.060 |
Why?
|
| Amyloid | 1 | 2007 | 73 | 0.060 |
Why?
|
| Corpus Striatum | 1 | 2007 | 98 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 296 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2007 | 154 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 52 | 0.060 |
Why?
|
| Intracranial Thrombosis | 1 | 2006 | 28 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 60 | 0.060 |
Why?
|
| Cerebral Angiography | 2 | 2014 | 299 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2006 | 261 | 0.060 |
Why?
|
| Ischemia | 1 | 2007 | 203 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 367 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 195 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2003 | 166 | 0.060 |
Why?
|
| Streptokinase | 1 | 2005 | 6 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 463 | 0.060 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 25 | 0.060 |
Why?
|
| Family Health | 1 | 2005 | 68 | 0.060 |
Why?
|
| Encephalitis Virus, Eastern Equine | 1 | 2024 | 1 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 112 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 27 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 291 | 0.060 |
Why?
|
| Thrombosis | 1 | 2007 | 206 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2007 | 223 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 198 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 78 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 309 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 78 | 0.050 |
Why?
|
| Risk | 1 | 2005 | 374 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 83 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2005 | 141 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 324 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2024 | 104 | 0.050 |
Why?
|
| tau Proteins | 1 | 2005 | 210 | 0.050 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.050 |
Why?
|
| Dipyridamole | 1 | 2003 | 17 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 324 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2006 | 483 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 136 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1270 | 0.050 |
Why?
|
| Diagnostic Errors | 2 | 1996 | 105 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 211 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2006 | 882 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 856 | 0.050 |
Why?
|
| Health Services | 1 | 2003 | 80 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1993 | 223 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2001 | 12 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 730 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2001 | 110 | 0.040 |
Why?
|
| Drug Carriers | 2 | 1993 | 188 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2001 | 231 | 0.040 |
Why?
|
| HIV Infections | 2 | 2000 | 955 | 0.040 |
Why?
|
| Electromyography | 2 | 1991 | 99 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 175 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 918 | 0.040 |
Why?
|
| Cell Line | 2 | 2001 | 2023 | 0.040 |
Why?
|
| Mice | 4 | 1994 | 11105 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 54 | 0.040 |
Why?
|
| Hemiplegia | 1 | 1998 | 4 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2000 | 637 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 371 | 0.030 |
Why?
|
| Radiography | 1 | 2019 | 555 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 1998 | 97 | 0.030 |
Why?
|
| Dementia, Multi-Infarct | 1 | 1996 | 4 | 0.030 |
Why?
|
| Brain Abscess | 1 | 1996 | 7 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1996 | 2 | 0.030 |
Why?
|
| Stavudine | 1 | 1996 | 3 | 0.030 |
Why?
|
| Naphthalenesulfonates | 1 | 1996 | 3 | 0.030 |
Why?
|
| Triage | 1 | 2017 | 135 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 122 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1996 | 28 | 0.030 |
Why?
|
| Child | 3 | 1991 | 4612 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 673 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1995 | 13 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 1995 | 12 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2001 | 1575 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 414 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 198 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2016 | 93 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 1996 | 149 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 1993 | 2284 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 216 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 130 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 171 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 420 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2145 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 261 | 0.030 |
Why?
|
| Virulence | 1 | 1994 | 199 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 292 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 58 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 919 | 0.020 |
Why?
|
| Endocytosis | 1 | 1992 | 152 | 0.020 |
Why?
|
| Paresthesia | 1 | 1989 | 7 | 0.020 |
Why?
|
| Neurons, Afferent | 1 | 1989 | 17 | 0.020 |
Why?
|
| Electroretinography | 1 | 1989 | 26 | 0.020 |
Why?
|
| Neural Conduction | 1 | 1989 | 32 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1989 | 89 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 699 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 431 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 1989 | 73 | 0.020 |
Why?
|
| Hydroxycholesterols | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1992 | 506 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 22 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 26 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1989 | 110 | 0.020 |
Why?
|
| Pyrroles | 1 | 2009 | 50 | 0.020 |
Why?
|
| Glaucoma | 1 | 1989 | 64 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 115 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 1988 | 9 | 0.020 |
Why?
|
| Motor Neurons | 1 | 1989 | 218 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 46 | 0.020 |
Why?
|
| United States | 2 | 2015 | 8094 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1988 | 199 | 0.020 |
Why?
|
| Vitamin D | 1 | 1988 | 139 | 0.020 |
Why?
|
| Papilledema | 1 | 1987 | 9 | 0.020 |
Why?
|
| Retinitis Pigmentosa | 1 | 1987 | 26 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 232 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1015 | 0.010 |
Why?
|
| Calcium | 1 | 1988 | 584 | 0.010 |
Why?
|
| Tennessee | 1 | 2003 | 17 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 170 | 0.010 |
Why?
|
| Viral Load | 1 | 2000 | 230 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 139 | 0.010 |
Why?
|
| Encephalomyelitis | 1 | 1998 | 4 | 0.010 |
Why?
|
| Adolescent | 1 | 1989 | 6305 | 0.010 |
Why?
|
| Medicare | 1 | 2003 | 624 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2000 | 574 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2000 | 1282 | 0.010 |
Why?
|
| Lamivudine | 1 | 1996 | 7 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1996 | 8 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1996 | 48 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 97 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 96 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 142 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1996 | 39 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1996 | 81 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 491 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 513 | 0.010 |
Why?
|
| Polymers | 1 | 1996 | 332 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 1994 | 0.010 |
Why?
|
| Monocytes | 1 | 1994 | 361 | 0.010 |
Why?
|
| Protein Binding | 1 | 1996 | 1639 | 0.010 |
Why?
|
| Foot Deformities, Congenital | 1 | 1987 | 2 | 0.000 |
Why?
|
| Hand Deformities, Congenital | 1 | 1987 | 4 | 0.000 |
Why?
|
| Blindness | 1 | 1987 | 43 | 0.000 |
Why?
|
| Fluorescein Angiography | 1 | 1987 | 63 | 0.000 |
Why?
|
| Syndrome | 1 | 1987 | 180 | 0.000 |
Why?
|